Sab biotherapeutics announces departure of chief financial officer

Miami, may 30, 2024 (globe newswire) -- sab biotherapeutics (nasdaq: sabs) (the “company” or “sab”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of t1d, today announced that effective june 4, its chief financial officer michael king will be departing the company to accept a role as ceo at a privately-held oncology company. he will continue as an advisor to sab through the end of the year.
SABS Ratings Summary
SABS Quant Ranking